People · Operator
Named in public records as an officer, director or promoter · active 2014–2023 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2014 |
| Tentarix Biotherapeutics, LP | — | Biotechnology | Series B | $43.0M | $358.6M | 2023 |
Donald J. Santel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Donald J. Santel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| Srinivas Akkaraju | 1 | 10 |
| James Healy | 1 | 8 |
| James I. Healy | 1 | 7 |
| Rob Hopfner | 1 | 6 |
| Jake Nunn | 1 | 5 |
| Bijan Salehizadeh | 1 | 5 |
| PAUL Grayson | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Jake R. Nunn | 1 | 4 |
| Donald Santel | 1 | 4 |
| Lota S Zoth | 1 | 4 |
| Gaurav Aggarwal | 1 | 3 |
| Robert Hopfner | 1 | 3 |
| DAVID GRYSKA | 1 | 3 |
| Cory Freedland | 1 | 3 |
| Christine A. Nash | 1 | 2 |
| Bo Jesper Hansen | 1 | 2 |
| Daniel G. Welch | 1 | 2 |
| Bijan R. Salehizadeh | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.